Moving Towards Targeted Therapies for Triple-Negative Breast Cancer.

ABSTRACT:

Purpose of review

In this review, we discuss targets of interest in Triple-negative breast cancer (TNBC), approved targeted agents and the results of the clinical trials that led to their approval. Additionally, we review ongoing clinical trials evaluating the use of novel targeted agents in the treatment of TNBC.

Recent findings

TNBC accounts for 15-20% of all breast cancer cases and is associated with worse clinical outcomes. Patients have a higher risk of metastatic recurrence and inferior overall survival compared to other breast cancer subtypes. Cytotoxic chemotherapy has historically been the mainstay of treatment for TNBC. In recent years, we have seen a surge in clinical trials investigating the use of targeted agents in TNBC and now have approval for targeted therap

SUBMITTER: Kagihara JA 

PROVIDER: S-EPMC8386298 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature